MNPR

+ Watchlist + Portfolio

Monopar Therapeutics Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $77.97
52-Week Range: $50.07 – $124.82
Market Cap: $523.35M
P/E (TTM): —
EPS (TTM): -2.20
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 4.00
PEG Ratio: —
Return on Equity: -19.50%
Return on Assets: -14.64%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 33.56
Debt/Equity: 0.00
Total Debt: $205.66K
Free Cash Flow: $-6.10M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $389.25M

MNPR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.59M	$5.60M	$13.01M	$9.90M
Selling, General & Admin	$2.95M	$3.23M	$3.16M	$6.80M
Operating Expenses	$10.54M	$8.83M	$16.16M	$16.70M
Operating Income	-$10.54M	-$8.83M	-$16.16M	-$16.70M
EBITDA	-$10.54M	-$8.83M	-$16.16M	-$16.70M
Pretax Income	-$10.52M	-$8.40M	-$15.59M	-$13.72M
Net Income	-$10.52M	-$8.40M	-$15.59M	-$13.72M
Diluted EPS	-4.15	-3.04	-4.11	-1.85
Diluted Shares	2.54M	2.76M	3.79M	7.41M

MNPR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.19M	$7.27M	$45.82M	$61.83M
Current Assets	$13.17M	$7.33M	$60.29M	$140.46M
Total Assets	$13.23M	$7.35M	$60.29M	$140.72M
Current Liabilities	$3.13M	$1.76M	$5.25M	$2.74M
Total Debt	$8.41K	$0.00	$0.00	$154.92K
Total Liabilities	$3.14M	$1.76M	$5.25M	$2.89M
Retained Earnings	-$51.80M	-$60.21M	-$75.79M	-$89.51M
Shareholders' Equity	$10.09M	$5.59M	$55.04M	$137.83M
Working Capital	$10.04M	$5.58M	$55.04M	$137.73M

MNPR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.23M	-$7.86M	-$6.40M	-$12.20M
Free Cash Flow	-$7.23M	-$7.86M	-$6.40M	-$12.20M
Stock-Based Compensation	$1.64M	$1.90M	$1.14M	$4.84M
Investing Cash Flow	-$4.92M	$4.93M	-$14.34M	-$63.45M
Financing Cash Flow	$32.87K	$2.03M	$59.29M	$91.57M
Share Repurchases	—	—	$0.00	-$35.00M
Net Change in Cash	-$12.11M	-$903.32K	$38.55M	$15.92M

MNPR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.64M	$1.73M	$2.59M	$3.94M	$3.49M	$4.77M
Selling, General & Admin	$1.58M	$1.50M	$1.50M	$2.21M	$1.74M	$1.88M
Operating Expenses	$3.22M	$3.23M	$4.09M	$6.16M	$5.23M	$6.64M
Operating Income	-$3.22M	-$3.23M	-$4.09M	-$6.16M	-$5.23M	-$6.64M
EBITDA	-$3.22M	-$3.23M	-$4.09M	-$6.16M	-$5.23M	-$6.64M
Pretax Income	-$2.62M	-$2.45M	-$3.44M	-$5.20M	-$3.89M	-$5.31M
Net Income	-$2.62M	-$2.45M	-$3.44M	-$5.20M	-$3.89M	-$5.31M
Diluted EPS	-0.38	-0.35	-0.48	—	-0.46	-0.62
Diluted Shares	6.99M	7.00M	7.12M	—	8.54M	8.54M

MNPR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$39.71M	$39.50M	$127.68M	$61.83M	$52.54M	$52.76M
Current Assets	$55.08M	$53.75M	$144.09M	$140.46M	$137.74M	$134.76M
Total Assets	$55.09M	$53.87M	$144.20M	$140.72M	$137.98M	$134.98M
Current Liabilities	$1.49M	$1.58M	$2.57M	$2.74M	$2.46M	$4.02M
Total Debt	—	$80.37K	$70.88K	$154.92K	$131.56K	$107.83K
Total Liabilities	$1.49M	$1.66M	$2.64M	$2.89M	$2.59M	$4.12M
Retained Earnings	-$78.42M	-$80.87M	-$84.31M	-$89.51M	-$93.40M	-$98.72M
Shareholders' Equity	$53.59M	$52.20M	$141.56M	$137.83M	$135.39M	$130.85M
Working Capital	$53.58M	$52.16M	$141.52M	$137.73M	$135.29M	$130.75M

MNPR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$5.66M	-$1.08M	-$2.09M	-$3.37M	-$3.47M	-$3.25M
Free Cash Flow	-$5.66M	-$1.08M	-$2.09M	-$3.37M	-$3.47M	-$3.25M
Stock-Based Compensation	$1.36M	$1.28M	$1.10M	$1.10M	$1.69M	$1.43M
Investing Cash Flow	-$325.83K	$1.19M	-$2.13M	-$62.19M	-$5.58M	$4.12M
Financing Cash Flow	-$115.68K	-$316.85K	$92.39M	-$384.68K	-$200.20K	-$647.39K
Share Repurchases	—	—	—	$0.00	—	—
Net Change in Cash	-$6.10M	-$206.92K	$88.18M	-$65.94M	-$9.26M	$220.65K

Market Snapshot

About

Monopar Therapeutics is a clinical-stage biopharmaceutical company developing proprietary therapeutics for cancer patients. The company focuses on camsirubicin for advanced soft tissue sarcoma and MNPR-101 for advanced cancers.